I wrote recently about re-usable pens (which I much prefer over the disposables). For years in Australia Novo Nordisk has provided two pens to use with their Penfill cartridges: NovoPen 4: 1U increments up to 60U/dose. NovoPen Echo: has memory of last dose size and time, 0.5U increments up to 30U. Of course, the older NovoPen …
In the last article I discussed what I think is a remarkable comparison between my recent personal data and the output of a 2019 CGM study of people without diabetes. At the end I showed a graph stretching over 20 years. It shows my HbA1c results over that time, overlaid with the TIR data from …
Further comparison with HCL and non-diabetic data Read More »
I’ve written multiple times about the benefits of using different ranges for Time In Range (see “Targets and Goals“). This is revisiting that topic in light of some recent experimental data. Like many this article has become quite long, but it’s split into sections: Terminology introduction, and choosing a new range based on published study …
I’ve mentioned previously a clinical trial I was involved in running, in which 20 people used AndroidAPS and research YpsoPumps. The next trial is now up and running. It’s called “CLOSE IT” (or sometimes CloseIt or Close-It) which stands for “Closed Loop Open SourcE In Type 1 diabetes”. No in case you’re wondering, I didn’t …
Ever since I wrote about the Anubis project (twice in 2021) I keep getting people assuming that I’m responsible for it. They send me requests for units, instructions as to how to make them themselves, etc. Just to be clear: I was one of the people involved in early testing of the units, and I …
I’ve reported previously about my experiences with insulin timings, including what happens when we go off-label and blend Humalog U100 with Lyumjev U100. I’ve now done another phase of experimentation, with a new data point. And some analysis of why these results might come about. I’ll first rewind a bit and explain that Humalog / …